First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Palbociclib + endocrine therapy
Sponsor: Pfizer